Published in Aliment Pharmacol Ther on September 15, 2003
Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med (2012) 3.27
Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology (2014) 3.04
Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 1.66
Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes (2008) 1.26
Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care (2011) 0.95
Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) (2015) 0.89
Blocking type I interferon signaling rescues lymphocytes from oxidative stress, exhaustion, and apoptosis in a streptozotocin-induced mouse model of type I diabetes. Oxid Med Cell Longev (2013) 0.86
Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol (2007) 0.83
Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol (2015) 0.82
Type I interferons mediate pancreatic toxicities of PERK inhibition. Proc Natl Acad Sci U S A (2015) 0.79
Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review. Clin Med Insights Endocrinol Diabetes (2011) 0.78
Clinical and genetic characteristics of patients with type 1 diabetes associated with interferon therapy. Diabetes Care (2011) 0.77
Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel) (2010) 0.75
Type B insulin resistance developing during interferon-alpha therapy. Endocr Pract (2009) 0.75
Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B. World J Gastroenterol (2008) 0.75
Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling. Proc Natl Acad Sci U S A (2017) 0.75
Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) (2017) 0.75
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
A test of the nature of cosmic acceleration using galaxy redshift distortions. Nature (2008) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis (2001) 2.50
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol (1996) 2.19
Anti-ganglioside antibodies in children with coeliac disease: correlation with gluten-free diet and neurological complications. Aliment Pharmacol Ther (2004) 2.18
Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet (1992) 2.13
Autoimmune hepatitis in childhood: a 20-year experience. Hepatology (1997) 1.97
Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy. Sex Transm Dis (1998) 1.87
Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. J Am Coll Cardiol (2001) 1.63
Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care (2000) 1.62
Premature ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab (2011) 1.60
Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology (2001) 1.59
Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med (2013) 1.57
T cell activation and disease severity in HIV infection. Clin Exp Immunol (1993) 1.53
Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin Chem (1995) 1.51
Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. Heart (2010) 1.51
Outpatient parenteral antibiotic therapy for bone and joint infections: an italian multicenter study. J Chemother (2007) 1.50
Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig Liver Dis (2002) 1.50
Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther (2012) 1.48
Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol (1995) 1.48
Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol (1979) 1.47
Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. J Gastroenterol (1999) 1.44
Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. The Collaborative Group. Gerontology (2000) 1.44
Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer (1999) 1.43
Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis (2003) 1.42
Antireticulin antibody in systemic sclerosis. Ann Rheum Dis (1990) 1.40
Insulin autoantibodies as markers of potential diabetes mellitus. Lancet (1989) 1.40
Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet (1991) 1.38
Shared amino acid sequences between glutamic acid decarboxylase 65 and 67 and alpha-2-macroglobulin. A focus for cross-reactive autoantibodies? Diabetologia (1995) 1.38
Outpatient parenteral antibiotic therapy in the elderly: an Italian observational multicenter study. J Chemother (2009) 1.38
Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol (1982) 1.37
Pathogenesis of insulin-dependent diabetes: a role for activated T lymphocytes. Lancet (1984) 1.34
Hepatitis B virus infection in prisons. A seroepidemiological survey in prisoners and attending staff. J Hyg (Lond) (1982) 1.32
De-novo autoimmune hepatitis after liver transplantation. Lancet (1998) 1.30
Virus, liver and autoimmunity. Dig Liver Dis (2001) 1.24
Epidemiology of HCV infection. Curr Pharm Des (2008) 1.23
Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol (1987) 1.23
HCV and autoimmunity. Curr Pharm Des (2008) 1.22
Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia (1996) 1.21
Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes? Clin Exp Immunol (1998) 1.18
Risk of type 1 diabetes development in children with incidental hyperglycemia: A multicenter Italian study. Diabetes Care (2001) 1.17
Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol (1998) 1.15
IgM reduction in systemic lupus erythematosus. Arthritis Rheum (1988) 1.15
Low serum C4 concentrations: an inherited predisposition to insulin dependent diabetes? Br Med J (Clin Res Ed) (1983) 1.15
Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis (1990) 1.14
Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients? J Acquir Immune Defic Syndr (2000) 1.14
Hepatic damage after exposure to halothane in medical personnel. Br J Anaesth (1981) 1.13
Clinical application of a new nephelometric technique to measure complement activation. J Clin Pathol (1983) 1.13
Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives. Diabetologia (1984) 1.12
Sensitisation to halothane-altered liver components in severe hepatic necrosis after halothane anaesthesia. Lancet (1978) 1.12
Auto-immune disorders in localized scleroderma. Arch Dermatol Res (1990) 1.12
Expression of intercellular adhesion molecule-1 (ICAM-1) on thyroid epithelial cells in Hashimoto's thyroiditis but not in Graves' disease or papillary thyroid cancer. Clin Exp Immunol (1991) 1.11
Immune changes associated with insulin dependent diabetes may remit without causing the disease: a study in identical twins. Br Med J (Clin Res Ed) (1986) 1.11
Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol (1998) 1.11
Histological evidence of hepatitis-B-virus infection with negative serology in children with acute leukaemia who develop chronic liver disease. Lancet (1982) 1.09
Natural course of subclinical hypothyroidism in Down's syndrome: prospective study results and therapeutic considerations. J Endocrinol Invest (1995) 1.08
Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg positive chronic liver disease. Gut (1982) 1.07
Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut (2005) 1.07
Investigation of a Q-fever outbreak in northern Italy. Eur J Epidemiol (1996) 1.04
Complement-fixing adrenal autoantibodies as a marker for predicting onset of idiopathic Addison's disease. Lancet (1983) 1.04
Lack of immunohistological changes in the islets of nondiabetic, autoimmune, polyendocrine patients with beta-selective GAD-specific islet cell antibodies. Diabetes (1994) 1.03
HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol (2008) 1.03
The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem (2001) 1.03
Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut (1995) 1.02
Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica (1985) 1.02
Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis (1989) 1.02
Activation of the complement system in systemic sclerosis. Relationship to clinical severity. Arthritis Rheum (1989) 1.01
Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin-producing cells. Arch Dermatol (1979) 1.01
Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I. Biochem Biophys Res Commun (2000) 1.01
Cell cycling in HIV infection: analysis of in vivo activated lymphocytes. Clin Exp Immunol (1995) 1.00
Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child (1992) 1.00
Clinical application of new technique that measures C4d for assessment of activation of classical complement pathway. J Clin Pathol (1988) 1.00
Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol (1986) 1.00
Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology (1989) 0.99
Vitiligo and polyglandular autoimmune disease with autoantibodies to melanin-producing cells. A new syndrome? Arch Dermatol (1981) 0.99
Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol (1993) 0.99
High intrafamilial variability in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case study. J Endocrinol Invest (2011) 0.99
Frequency of Hashimoto's thyroiditis in children with type 1 diabetes mellitus. Acta Diabetol (1995) 0.98
Increase in simultaneous coexpression of naive and memory lymphocyte markers at diagnosis of IDDM. Diabetes (1993) 0.98
Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab (1996) 0.98
Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol (1998) 0.98
Hepatitis A infection: a seroepidemiological study in young adults in North-East Italy. Eur J Epidemiol (1997) 0.97
Immune factors in narcolepsy. Sleep (1986) 0.97
Naturally occurring soluble CD4 in patients with human immunodeficiency virus infection. J Infect Dis (1992) 0.97
Graft-versus-host disease after orthotopic liver transplantation in a child. Transplant Proc (1990) 0.97
Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. J Hepatol (1994) 0.97
T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet (1991) 0.97
Molecular background and genotype-phenotype correlation in autoimmune-polyendocrinopathy-candidiasis-ectodermal-distrophy patients from Campania and in their relatives. J Endocrinol Invest (2011) 0.96
A novel mutation in the thyrotropin (TSH) receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. J Clin Endocrinol Metab (2000) 0.96
Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity. Scand J Gastroenterol (2004) 0.96
Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig Liver Dis (2002) 0.95
Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol (2003) 0.95